| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 70 | 2024 | 742 | 17.840 |
Why?
|
| Endocrinology | 16 | 2022 | 49 | 11.850 |
Why?
|
| Diabetes Mellitus, Type 2 | 69 | 2024 | 1180 | 11.620 |
Why?
|
| Hypoglycemic Agents | 40 | 2024 | 351 | 6.320 |
Why?
|
| Blood Glucose | 48 | 2024 | 837 | 5.530 |
Why?
|
| Diabetes Mellitus, Type 1 | 21 | 2024 | 565 | 4.250 |
Why?
|
| Medicaid | 12 | 2024 | 233 | 4.020 |
Why?
|
| Aging | 23 | 2023 | 720 | 3.810 |
Why?
|
| Blood Glucose Self-Monitoring | 13 | 2022 | 54 | 3.150 |
Why?
|
| Reference Standards | 16 | 2022 | 144 | 3.050 |
Why?
|
| Standard of Care | 16 | 2022 | 65 | 3.050 |
Why?
|
| Diabetes Complications | 20 | 2024 | 170 | 2.890 |
Why?
|
| Community Health Centers | 14 | 2023 | 117 | 2.740 |
Why?
|
| Hypoglycemia | 19 | 2024 | 107 | 2.720 |
Why?
|
| United States | 77 | 2024 | 7025 | 2.570 |
Why?
|
| Aged | 107 | 2024 | 19252 | 2.520 |
Why?
|
| Humans | 225 | 2024 | 89675 | 2.510 |
Why?
|
| Societies, Medical | 16 | 2022 | 579 | 2.390 |
Why?
|
| Cost-Benefit Analysis | 23 | 2024 | 463 | 2.350 |
Why?
|
| Healthcare Disparities | 13 | 2016 | 422 | 2.170 |
Why?
|
| Insulin | 17 | 2024 | 1148 | 2.100 |
Why?
|
| Cardiovascular Diseases | 13 | 2024 | 714 | 1.880 |
Why?
|
| Female | 129 | 2024 | 46391 | 1.770 |
Why?
|
| Male | 125 | 2024 | 42581 | 1.760 |
Why?
|
| Middle Aged | 95 | 2024 | 26086 | 1.720 |
Why?
|
| Quality of Life | 21 | 2023 | 1675 | 1.650 |
Why?
|
| Primary Health Care | 13 | 2022 | 352 | 1.580 |
Why?
|
| Quality-Adjusted Life Years | 14 | 2024 | 144 | 1.400 |
Why?
|
| Aged, 80 and over | 37 | 2024 | 6842 | 1.290 |
Why?
|
| Patient Protection and Affordable Care Act | 5 | 2022 | 67 | 1.260 |
Why?
|
| Adult | 72 | 2024 | 26708 | 1.230 |
Why?
|
| Insurance, Health | 5 | 2016 | 162 | 1.200 |
Why?
|
| Insurance Coverage | 6 | 2019 | 120 | 1.200 |
Why?
|
| Ambulatory Care Facilities | 6 | 2022 | 111 | 1.180 |
Why?
|
| Cross-Sectional Studies | 23 | 2024 | 1720 | 1.160 |
Why?
|
| Health Services for the Aged | 3 | 2015 | 32 | 1.070 |
Why?
|
| Quality Improvement | 7 | 2022 | 455 | 1.070 |
Why?
|
| Health Expenditures | 4 | 2016 | 91 | 1.050 |
Why?
|
| Comorbidity | 16 | 2022 | 951 | 1.040 |
Why?
|
| Minority Groups | 4 | 2024 | 147 | 1.040 |
Why?
|
| Social Support | 4 | 2024 | 213 | 1.030 |
Why?
|
| Dementia | 8 | 2024 | 200 | 1.020 |
Why?
|
| Health Status | 10 | 2023 | 371 | 1.020 |
Why?
|
| Decision Support Techniques | 4 | 2016 | 168 | 0.990 |
Why?
|
| Risk Factors | 28 | 2024 | 5517 | 0.990 |
Why?
|
| Longitudinal Studies | 14 | 2024 | 1076 | 0.980 |
Why?
|
| Delivery of Health Care | 7 | 2023 | 436 | 0.970 |
Why?
|
| Appointments and Schedules | 2 | 2019 | 54 | 0.950 |
Why?
|
| Risk Assessment | 13 | 2024 | 2305 | 0.940 |
Why?
|
| Health Facility Closure | 1 | 2024 | 7 | 0.930 |
Why?
|
| Propensity Score | 2 | 2024 | 148 | 0.920 |
Why?
|
| Health Status Disparities | 5 | 2016 | 189 | 0.900 |
Why?
|
| Precision Medicine | 4 | 2019 | 413 | 0.900 |
Why?
|
| Insulin Infusion Systems | 4 | 2023 | 37 | 0.880 |
Why?
|
| Chronic Disease | 5 | 2016 | 950 | 0.870 |
Why?
|
| Health Care Costs | 7 | 2024 | 235 | 0.860 |
Why?
|
| Frailty | 2 | 2021 | 78 | 0.860 |
Why?
|
| Hypertension | 6 | 2024 | 747 | 0.860 |
Why?
|
| Eligibility Determination | 3 | 2022 | 36 | 0.850 |
Why?
|
| Safety-net Providers | 5 | 2019 | 37 | 0.850 |
Why?
|
| Adolescent | 29 | 2024 | 9290 | 0.840 |
Why?
|
| Patient-Centered Care | 10 | 2022 | 209 | 0.830 |
Why?
|
| Quality of Health Care | 8 | 2022 | 386 | 0.820 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2023 | 261 | 0.790 |
Why?
|
| Patient Satisfaction | 7 | 2012 | 460 | 0.790 |
Why?
|
| Obesity | 5 | 2023 | 972 | 0.750 |
Why?
|
| Hospitalization | 7 | 2020 | 880 | 0.740 |
Why?
|
| Medication Adherence | 3 | 2019 | 140 | 0.740 |
Why?
|
| Genetic Testing | 3 | 2019 | 540 | 0.740 |
Why?
|
| Retinal Diseases | 1 | 2022 | 90 | 0.730 |
Why?
|
| Cohort Studies | 18 | 2024 | 2879 | 0.720 |
Why?
|
| Disabled Persons | 1 | 2021 | 73 | 0.720 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 219 | 0.720 |
Why?
|
| Young Adult | 25 | 2024 | 6350 | 0.720 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2019 | 31 | 0.720 |
Why?
|
| Children's Health Insurance Program | 1 | 2020 | 2 | 0.700 |
Why?
|
| Public Sector | 1 | 2020 | 12 | 0.700 |
Why?
|
| Private Sector | 1 | 2020 | 19 | 0.690 |
Why?
|
| Electronic Health Records | 9 | 2024 | 351 | 0.690 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2017 | 59 | 0.680 |
Why?
|
| Financing, Personal | 2 | 2016 | 21 | 0.680 |
Why?
|
| Comparative Effectiveness Research | 2 | 2023 | 53 | 0.670 |
Why?
|
| Polypharmacy | 3 | 2016 | 15 | 0.670 |
Why?
|
| Logistic Models | 10 | 2024 | 1214 | 0.670 |
Why?
|
| Child | 20 | 2024 | 7202 | 0.670 |
Why?
|
| Life Expectancy | 7 | 2023 | 89 | 0.650 |
Why?
|
| Physicians | 4 | 2019 | 690 | 0.620 |
Why?
|
| Residence Characteristics | 3 | 2017 | 202 | 0.620 |
Why?
|
| Caregivers | 3 | 2024 | 166 | 0.600 |
Why?
|
| Odds Ratio | 7 | 2015 | 683 | 0.600 |
Why?
|
| Health Services Needs and Demand | 3 | 2024 | 107 | 0.580 |
Why?
|
| Frail Elderly | 4 | 2021 | 82 | 0.580 |
Why?
|
| Quality Assurance, Health Care | 6 | 2012 | 225 | 0.570 |
Why?
|
| California | 11 | 2024 | 146 | 0.560 |
Why?
|
| Geriatric Assessment | 4 | 2021 | 182 | 0.550 |
Why?
|
| Hypercholesterolemia | 2 | 2017 | 159 | 0.550 |
Why?
|
| Public Health | 2 | 2012 | 140 | 0.550 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 3671 | 0.540 |
Why?
|
| Child Health Services | 1 | 2016 | 48 | 0.540 |
Why?
|
| Telemedicine | 1 | 2019 | 188 | 0.540 |
Why?
|
| Blood Pressure | 8 | 2019 | 901 | 0.540 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 111 | 0.530 |
Why?
|
| Physicians, Primary Care | 2 | 2015 | 105 | 0.530 |
Why?
|
| Home Care Services | 1 | 2017 | 73 | 0.520 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 377 | 0.520 |
Why?
|
| Drug Labeling | 1 | 2015 | 41 | 0.510 |
Why?
|
| Physicians, Family | 2 | 2008 | 39 | 0.510 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 74 | 0.510 |
Why?
|
| Health Policy | 2 | 2015 | 186 | 0.500 |
Why?
|
| Diabetic Foot | 4 | 2019 | 14 | 0.500 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 136 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 605 | 0.490 |
Why?
|
| Drug Costs | 4 | 2021 | 63 | 0.490 |
Why?
|
| Body Mass Index | 7 | 2023 | 774 | 0.490 |
Why?
|
| Forecasting | 3 | 2013 | 306 | 0.480 |
Why?
|
| Monitoring, Ambulatory | 5 | 2018 | 32 | 0.480 |
Why?
|
| Medically Underserved Area | 2 | 2022 | 27 | 0.480 |
Why?
|
| Retrospective Studies | 18 | 2023 | 9091 | 0.470 |
Why?
|
| Socioeconomic Factors | 9 | 2017 | 591 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2023 | 845 | 0.470 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 3 | 2023 | 36 | 0.460 |
Why?
|
| Federal Government | 2 | 2014 | 29 | 0.460 |
Why?
|
| Preventive Health Services | 1 | 2014 | 39 | 0.450 |
Why?
|
| Medicare | 6 | 2020 | 425 | 0.440 |
Why?
|
| Health Care Reform | 2 | 2015 | 85 | 0.440 |
Why?
|
| Heart Transplantation | 4 | 2020 | 717 | 0.440 |
Why?
|
| Office Visits | 2 | 2017 | 50 | 0.440 |
Why?
|
| Costs and Cost Analysis | 4 | 2023 | 153 | 0.440 |
Why?
|
| Age Factors | 10 | 2021 | 1874 | 0.440 |
Why?
|
| Surveys and Questionnaires | 12 | 2024 | 2641 | 0.430 |
Why?
|
| Decision Making | 2 | 2016 | 668 | 0.430 |
Why?
|
| Registries | 6 | 2020 | 791 | 0.430 |
Why?
|
| Osteoporotic Fractures | 2 | 2024 | 47 | 0.430 |
Why?
|
| Referral and Consultation | 3 | 2021 | 342 | 0.430 |
Why?
|
| Models, Theoretical | 2 | 2013 | 492 | 0.420 |
Why?
|
| Gastrointestinal Agents | 2 | 2021 | 172 | 0.420 |
Why?
|
| Pediatrics | 1 | 2016 | 357 | 0.410 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 374 | 0.410 |
Why?
|
| Disease Management | 5 | 2016 | 329 | 0.410 |
Why?
|
| Language | 1 | 2014 | 156 | 0.400 |
Why?
|
| Insurance Claim Review | 2 | 2024 | 45 | 0.400 |
Why?
|
| Health Services Research | 6 | 2017 | 137 | 0.400 |
Why?
|
| Incidence | 10 | 2017 | 1598 | 0.400 |
Why?
|
| Program Evaluation | 3 | 2014 | 308 | 0.400 |
Why?
|
| Bariatric Surgery | 2 | 2014 | 197 | 0.390 |
Why?
|
| Sulfonylurea Compounds | 3 | 2024 | 65 | 0.390 |
Why?
|
| Chicago | 9 | 2024 | 1432 | 0.390 |
Why?
|
| Models, Biological | 1 | 2019 | 1767 | 0.390 |
Why?
|
| Depression | 6 | 2013 | 509 | 0.380 |
Why?
|
| Health Services Accessibility | 7 | 2022 | 431 | 0.380 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 214 | 0.380 |
Why?
|
| Total Quality Management | 2 | 2008 | 33 | 0.370 |
Why?
|
| Prevalence | 7 | 2017 | 1246 | 0.370 |
Why?
|
| Biomarkers | 6 | 2019 | 1771 | 0.370 |
Why?
|
| Mass Screening | 5 | 2024 | 641 | 0.360 |
Why?
|
| Program Development | 2 | 2007 | 123 | 0.350 |
Why?
|
| Disease Progression | 5 | 2024 | 1492 | 0.350 |
Why?
|
| Databases, Factual | 3 | 2019 | 858 | 0.350 |
Why?
|
| Physician-Patient Relations | 4 | 2016 | 626 | 0.340 |
Why?
|
| Health Surveys | 5 | 2021 | 240 | 0.340 |
Why?
|
| Pancreatic Cyst | 1 | 2009 | 28 | 0.340 |
Why?
|
| Data Accuracy | 2 | 2023 | 32 | 0.340 |
Why?
|
| Population Density | 1 | 2009 | 61 | 0.340 |
Why?
|
| Accidental Falls | 1 | 2009 | 50 | 0.330 |
Why?
|
| Health Facility Administrators | 2 | 2010 | 15 | 0.330 |
Why?
|
| Cost of Illness | 1 | 2009 | 148 | 0.320 |
Why?
|
| Self Care | 5 | 2013 | 165 | 0.320 |
Why?
|
| Markov Chains | 4 | 2021 | 127 | 0.320 |
Why?
|
| Metformin | 3 | 2024 | 124 | 0.320 |
Why?
|
| Professional-Patient Relations | 3 | 2014 | 54 | 0.310 |
Why?
|
| Burnout, Professional | 4 | 2019 | 102 | 0.310 |
Why?
|
| Drug Therapy | 1 | 2008 | 70 | 0.310 |
Why?
|
| Hospitals | 2 | 2022 | 301 | 0.310 |
Why?
|
| Emergency Service, Hospital | 3 | 2018 | 522 | 0.300 |
Why?
|
| Rifamycins | 1 | 2007 | 6 | 0.300 |
Why?
|
| Quality Indicators, Health Care | 3 | 2020 | 147 | 0.300 |
Why?
|
| Genomics | 1 | 2013 | 777 | 0.300 |
Why?
|
| Attitude of Health Personnel | 7 | 2019 | 651 | 0.290 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 364 | 0.290 |
Why?
|
| Lactulose | 1 | 2007 | 22 | 0.290 |
Why?
|
| Diabetic Retinopathy | 3 | 2016 | 91 | 0.290 |
Why?
|
| Financial Management | 1 | 2007 | 21 | 0.290 |
Why?
|
| Hepatic Encephalopathy | 1 | 2007 | 39 | 0.290 |
Why?
|
| Laboratories, Hospital | 1 | 2007 | 8 | 0.290 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 1728 | 0.290 |
Why?
|
| Treatment Outcome | 11 | 2019 | 8276 | 0.290 |
Why?
|
| Prescription Drugs | 2 | 2020 | 36 | 0.290 |
Why?
|
| Liver Failure | 1 | 2007 | 67 | 0.290 |
Why?
|
| Preoperative Care | 1 | 2009 | 395 | 0.290 |
Why?
|
| Morale | 4 | 2019 | 16 | 0.290 |
Why?
|
| Health Plan Implementation | 1 | 2007 | 56 | 0.280 |
Why?
|
| Computer Simulation | 3 | 2024 | 1100 | 0.280 |
Why?
|
| Patient Care Management | 2 | 2011 | 30 | 0.280 |
Why?
|
| Infant | 4 | 2021 | 3168 | 0.280 |
Why?
|
| Monte Carlo Method | 3 | 2017 | 187 | 0.280 |
Why?
|
| Time Factors | 8 | 2019 | 5344 | 0.270 |
Why?
|
| Job Satisfaction | 3 | 2019 | 79 | 0.270 |
Why?
|
| Attitude to Health | 3 | 2016 | 223 | 0.260 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 283 | 0.260 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 265 | 0.260 |
Why?
|
| Goals | 2 | 2006 | 67 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1049 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 790 | 0.250 |
Why?
|
| Colorado | 3 | 2021 | 37 | 0.250 |
Why?
|
| Systems Analysis | 2 | 2021 | 17 | 0.240 |
Why?
|
| Self-Assessment | 1 | 2005 | 47 | 0.240 |
Why?
|
| Interviews as Topic | 6 | 2016 | 344 | 0.240 |
Why?
|
| Oregon | 2 | 2022 | 26 | 0.240 |
Why?
|
| Child, Preschool | 4 | 2021 | 3748 | 0.240 |
Why?
|
| Tissue and Organ Procurement | 2 | 2020 | 350 | 0.240 |
Why?
|
| Community Networks | 2 | 2021 | 30 | 0.240 |
Why?
|
| Loneliness | 1 | 2024 | 27 | 0.240 |
Why?
|
| Texas | 1 | 2024 | 115 | 0.230 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2004 | 23 | 0.230 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 856 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 687 | 0.220 |
Why?
|
| Health Personnel | 2 | 2019 | 215 | 0.220 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 2765 | 0.220 |
Why?
|
| Needs Assessment | 1 | 2024 | 161 | 0.220 |
Why?
|
| Hip Fractures | 1 | 2023 | 46 | 0.220 |
Why?
|
| Tool Use Behavior | 1 | 2023 | 13 | 0.220 |
Why?
|
| Biological Transport | 1 | 2024 | 401 | 0.220 |
Why?
|
| Drug Utilization | 3 | 2016 | 66 | 0.220 |
Why?
|
| Rural Population | 1 | 2024 | 146 | 0.220 |
Why?
|
| Cholesterol | 3 | 2019 | 360 | 0.210 |
Why?
|
| Activities of Daily Living | 4 | 2017 | 207 | 0.210 |
Why?
|
| Washington | 1 | 2022 | 49 | 0.210 |
Why?
|
| Patient Care Team | 2 | 2010 | 285 | 0.210 |
Why?
|
| New York | 1 | 2022 | 72 | 0.210 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.210 |
Why?
|
| Patient Participation | 2 | 2016 | 226 | 0.210 |
Why?
|
| Cystitis | 1 | 2002 | 14 | 0.200 |
Why?
|
| Diabetic Neuropathies | 2 | 2016 | 41 | 0.200 |
Why?
|
| Waiting Lists | 2 | 2020 | 184 | 0.200 |
Why?
|
| Antihypertensive Agents | 2 | 2016 | 251 | 0.200 |
Why?
|
| Postural Balance | 1 | 2021 | 46 | 0.200 |
Why?
|
| Health Information Exchange | 1 | 2021 | 12 | 0.200 |
Why?
|
| Awards and Prizes | 1 | 2022 | 37 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 156 | 0.200 |
Why?
|
| Medical Informatics | 1 | 2022 | 49 | 0.200 |
Why?
|
| Diabetic Nephropathies | 2 | 2016 | 87 | 0.200 |
Why?
|
| Accelerometry | 2 | 2021 | 40 | 0.200 |
Why?
|
| Hyperglycemia | 5 | 2014 | 172 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2023 | 4311 | 0.190 |
Why?
|
| Urinary Tract Infections | 1 | 2002 | 76 | 0.190 |
Why?
|
| Cultural Competency | 1 | 2021 | 21 | 0.190 |
Why?
|
| Medical Overuse | 2 | 2018 | 36 | 0.190 |
Why?
|
| Communication | 2 | 2016 | 458 | 0.190 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 179 | 0.190 |
Why?
|
| Walking | 1 | 2021 | 92 | 0.190 |
Why?
|
| Fungemia | 1 | 2020 | 15 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2002 | 188 | 0.180 |
Why?
|
| Anticholesteremic Agents | 1 | 2001 | 141 | 0.180 |
Why?
|
| Liver Transplantation | 1 | 2007 | 1171 | 0.180 |
Why?
|
| Mesalamine | 1 | 2021 | 88 | 0.180 |
Why?
|
| Body Temperature | 1 | 2020 | 125 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2016 | 873 | 0.170 |
Why?
|
| Poverty Areas | 1 | 2020 | 37 | 0.170 |
Why?
|
| Diabetic Angiopathies | 2 | 2017 | 37 | 0.170 |
Why?
|
| Health Care Surveys | 5 | 2019 | 281 | 0.170 |
Why?
|
| Infant, Newborn | 2 | 2020 | 2487 | 0.170 |
Why?
|
| Bacteremia | 1 | 2020 | 102 | 0.170 |
Why?
|
| Piperidines | 1 | 2021 | 166 | 0.170 |
Why?
|
| Fever | 1 | 2020 | 128 | 0.170 |
Why?
|
| State Health Plans | 1 | 2019 | 14 | 0.170 |
Why?
|
| Phenotype | 3 | 2021 | 2450 | 0.170 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 72 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 64 | 0.170 |
Why?
|
| Confidence Intervals | 2 | 2009 | 225 | 0.170 |
Why?
|
| Withholding Treatment | 1 | 2019 | 117 | 0.160 |
Why?
|
| Insulin, Isophane | 1 | 2018 | 2 | 0.160 |
Why?
|
| Insulin Detemir | 1 | 2018 | 3 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 242 | 0.160 |
Why?
|
| Insulin Glargine | 1 | 2018 | 9 | 0.160 |
Why?
|
| Early Medical Intervention | 1 | 2018 | 20 | 0.160 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 496 | 0.160 |
Why?
|
| Endometrial Neoplasms | 1 | 2021 | 208 | 0.160 |
Why?
|
| United Kingdom | 2 | 2024 | 164 | 0.150 |
Why?
|
| Machine Learning | 1 | 2020 | 263 | 0.150 |
Why?
|
| Exercise | 1 | 2021 | 325 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 2019 | 0.150 |
Why?
|
| Blood Specimen Collection | 2 | 2014 | 27 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2021 | 375 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2020 | 388 | 0.150 |
Why?
|
| Sex Factors | 3 | 2018 | 1068 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 192 | 0.150 |
Why?
|
| Cost Savings | 1 | 2017 | 69 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 988 | 0.140 |
Why?
|
| Medically Uninsured | 2 | 2014 | 59 | 0.140 |
Why?
|
| Models, Statistical | 3 | 2020 | 576 | 0.140 |
Why?
|
| Health Promotion | 1 | 2019 | 165 | 0.140 |
Why?
|
| Gangrene | 1 | 2016 | 7 | 0.140 |
Why?
|
| Veterans Health | 1 | 2016 | 16 | 0.140 |
Why?
|
| Osteomyelitis | 1 | 2016 | 55 | 0.140 |
Why?
|
| Smoking Cessation | 1 | 2019 | 254 | 0.140 |
Why?
|
| Prognosis | 4 | 2020 | 3801 | 0.140 |
Why?
|
| Glycemic Index | 1 | 2016 | 10 | 0.140 |
Why?
|
| Motivation | 4 | 2021 | 296 | 0.140 |
Why?
|
| Perception | 2 | 2008 | 179 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 606 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 54 | 0.130 |
Why?
|
| Protein Precursors | 2 | 2013 | 140 | 0.130 |
Why?
|
| Coronary Disease | 1 | 2017 | 260 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 449 | 0.130 |
Why?
|
| Drug Utilization Review | 1 | 2015 | 14 | 0.130 |
Why?
|
| Organizational Culture | 1 | 2016 | 34 | 0.130 |
Why?
|
| Pandemics | 1 | 2022 | 776 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 151 | 0.130 |
Why?
|
| Patient Preference | 1 | 2016 | 111 | 0.130 |
Why?
|
| Motor Activity | 1 | 2018 | 327 | 0.130 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 41 | 0.130 |
Why?
|
| Long-Term Care | 1 | 2016 | 61 | 0.130 |
Why?
|
| Philippines | 1 | 2015 | 22 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 160 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 49 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1369 | 0.120 |
Why?
|
| Anthropometry | 1 | 2014 | 76 | 0.120 |
Why?
|
| Pregnancy | 1 | 2022 | 3025 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2017 | 257 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2014 | 102 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 234 | 0.110 |
Why?
|
| Heart Failure | 2 | 2020 | 1188 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 740 | 0.110 |
Why?
|
| Carrier State | 1 | 2013 | 39 | 0.110 |
Why?
|
| Bacteriological Techniques | 1 | 2013 | 39 | 0.110 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2013 | 30 | 0.110 |
Why?
|
| Calcitonin | 1 | 2013 | 38 | 0.110 |
Why?
|
| Patient Access to Records | 1 | 2013 | 2 | 0.110 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 226 | 0.110 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 80 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 78 | 0.110 |
Why?
|
| Intention | 1 | 2013 | 52 | 0.110 |
Why?
|
| Demography | 1 | 2013 | 183 | 0.100 |
Why?
|
| Models, Economic | 2 | 2024 | 62 | 0.100 |
Why?
|
| Risk | 4 | 2016 | 657 | 0.100 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 10 | 0.100 |
Why?
|
| Survival Rate | 2 | 2014 | 1909 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 360 | 0.100 |
Why?
|
| Remission Induction | 1 | 2014 | 741 | 0.100 |
Why?
|
| Brain | 2 | 2018 | 2289 | 0.100 |
Why?
|
| Trust | 1 | 2013 | 98 | 0.100 |
Why?
|
| Linear Models | 1 | 2013 | 421 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 277 | 0.100 |
Why?
|
| Neoplasms | 2 | 2017 | 3080 | 0.100 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 60 | 0.100 |
Why?
|
| Career Choice | 1 | 2013 | 148 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2011 | 7 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2011 | 103 | 0.090 |
Why?
|
| Sodium | 2 | 2022 | 331 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 271 | 0.090 |
Why?
|
| Mental Health | 1 | 2012 | 178 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2568 | 0.090 |
Why?
|
| Medical Informatics Applications | 1 | 2010 | 9 | 0.090 |
Why?
|
| Cost Sharing | 1 | 2010 | 17 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2019 | 1535 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 2023 | 0.090 |
Why?
|
| Cost Control | 1 | 2010 | 45 | 0.090 |
Why?
|
| Massachusetts | 2 | 2014 | 33 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 160 | 0.090 |
Why?
|
| Osteosarcoma | 1 | 2011 | 161 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2010 | 82 | 0.090 |
Why?
|
| Budgets | 1 | 2009 | 10 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2010 | 158 | 0.090 |
Why?
|
| Government Programs | 1 | 2009 | 8 | 0.090 |
Why?
|
| Prejudice | 1 | 2009 | 48 | 0.080 |
Why?
|
| Triglycerides | 2 | 2017 | 232 | 0.080 |
Why?
|
| Glucose | 2 | 2022 | 630 | 0.080 |
Why?
|
| Endosonography | 1 | 2009 | 99 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2009 | 144 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 329 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 539 | 0.080 |
Why?
|
| Social Identification | 1 | 2008 | 26 | 0.080 |
Why?
|
| Personnel Management | 1 | 2008 | 7 | 0.080 |
Why?
|
| Interview, Psychological | 1 | 2008 | 69 | 0.080 |
Why?
|
| Sample Size | 1 | 2008 | 128 | 0.080 |
Why?
|
| Los Angeles | 1 | 2007 | 28 | 0.070 |
Why?
|
| Cost Allocation | 1 | 2007 | 5 | 0.070 |
Why?
|
| Midwestern United States | 1 | 2007 | 82 | 0.070 |
Why?
|
| Specialization | 2 | 2008 | 66 | 0.070 |
Why?
|
| Peer Group | 1 | 2008 | 81 | 0.070 |
Why?
|
| Sexual Behavior | 1 | 2010 | 311 | 0.070 |
Why?
|
| Parents | 1 | 2010 | 288 | 0.070 |
Why?
|
| Reimbursement, Incentive | 1 | 2007 | 37 | 0.070 |
Why?
|
| Poverty | 2 | 2019 | 181 | 0.070 |
Why?
|
| Health Behavior | 2 | 2008 | 186 | 0.070 |
Why?
|
| Policy Making | 1 | 2007 | 62 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2008 | 231 | 0.070 |
Why?
|
| Medicine | 2 | 2008 | 91 | 0.070 |
Why?
|
| Cultural Diversity | 1 | 2007 | 57 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 415 | 0.070 |
Why?
|
| Leadership | 1 | 2008 | 138 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2007 | 172 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1864 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2005 | 22 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 972 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 983 | 0.060 |
Why?
|
| Life Change Events | 1 | 2005 | 48 | 0.060 |
Why?
|
| Resource Allocation | 2 | 2019 | 65 | 0.060 |
Why?
|
| Masculinity | 1 | 2024 | 16 | 0.060 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 9 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 48 | 0.060 |
Why?
|
| Illinois | 1 | 2006 | 483 | 0.060 |
Why?
|
| Calibration | 1 | 2024 | 103 | 0.060 |
Why?
|
| Synaptic Membranes | 1 | 2004 | 14 | 0.060 |
Why?
|
| Self-Management | 1 | 2024 | 42 | 0.060 |
Why?
|
| Niemann-Pick Diseases | 1 | 2004 | 6 | 0.060 |
Why?
|
| Friends | 1 | 2023 | 20 | 0.060 |
Why?
|
| Family Practice | 1 | 2004 | 82 | 0.050 |
Why?
|
| Cognition | 2 | 2018 | 579 | 0.050 |
Why?
|
| Health Resources | 1 | 2004 | 81 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 4 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 147 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 47 | 0.050 |
Why?
|
| Bone Density | 1 | 2023 | 209 | 0.050 |
Why?
|
| Urinalysis | 1 | 2002 | 31 | 0.050 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2011 | 5 | 0.050 |
Why?
|
| Decision Trees | 1 | 2021 | 59 | 0.050 |
Why?
|
| Vulnerable Populations | 2 | 2014 | 83 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 385 | 0.050 |
Why?
|
| Jurisprudence | 1 | 2021 | 25 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 53 | 0.050 |
Why?
|
| Deprescriptions | 1 | 2021 | 6 | 0.050 |
Why?
|
| Exercise Test | 1 | 2021 | 166 | 0.050 |
Why?
|
| Blood Culture | 1 | 2020 | 10 | 0.050 |
Why?
|
| Equipment Design | 1 | 2012 | 420 | 0.050 |
Why?
|
| Quinolines | 1 | 2021 | 91 | 0.050 |
Why?
|
| Antipyretics | 1 | 2020 | 2 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 115 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 512 | 0.050 |
Why?
|
| Health Education | 1 | 2011 | 105 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 29 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2002 | 590 | 0.040 |
Why?
|
| Troponin | 1 | 2020 | 24 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 131 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 740 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 681 | 0.040 |
Why?
|
| Infliximab | 1 | 2021 | 159 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 92 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 312 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 900 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 34 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 89 | 0.040 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 78 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 601 | 0.040 |
Why?
|
| Creatinine | 1 | 2020 | 294 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2021 | 479 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 434 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 23 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1848 | 0.040 |
Why?
|
| Population Health | 1 | 2019 | 33 | 0.040 |
Why?
|
| Age Distribution | 2 | 2012 | 200 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 787 | 0.040 |
Why?
|
| Systole | 1 | 2018 | 115 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2018 | 121 | 0.040 |
Why?
|
| Biological Products | 1 | 2021 | 155 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2368 | 0.040 |
Why?
|
| Glycoproteins | 2 | 2013 | 234 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 130 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 970 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 183 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 370 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 261 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 14 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2017 | 111 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2016 | 20 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2016 | 21 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 83 | 0.030 |
Why?
|
| Microvessels | 1 | 2016 | 69 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 506 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 119 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 149 | 0.030 |
Why?
|
| Medicare Part A | 1 | 2015 | 3 | 0.030 |
Why?
|
| Medicare Part B | 1 | 2015 | 3 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 173 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 50 | 0.030 |
Why?
|
| Neurons | 1 | 2004 | 1585 | 0.030 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2014 | 2 | 0.030 |
Why?
|
| Urine Specimen Collection | 1 | 2014 | 4 | 0.030 |
Why?
|
| Idaho | 1 | 2014 | 8 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 302 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 95 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1993 | 66 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 39 | 0.030 |
Why?
|
| Saliva | 1 | 2014 | 124 | 0.030 |
Why?
|
| Indians, North American | 1 | 2013 | 47 | 0.030 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2013 | 40 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 3016 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 1852 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1993 | 136 | 0.030 |
Why?
|
| Personnel Turnover | 1 | 2013 | 9 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2013 | 61 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2013 | 47 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2014 | 302 | 0.030 |
Why?
|
| Educational Status | 1 | 2013 | 195 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 106 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 26 | 0.030 |
Why?
|
| Prediabetic State | 1 | 2012 | 36 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 145 | 0.030 |
Why?
|
| Infection Control | 1 | 2013 | 122 | 0.030 |
Why?
|
| Cross Infection | 1 | 2013 | 149 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2012 | 171 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 492 | 0.020 |
Why?
|
| Mice | 3 | 2011 | 11807 | 0.020 |
Why?
|
| Proxy | 1 | 2011 | 26 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2011 | 69 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 864 | 0.020 |
Why?
|
| Algorithms | 2 | 2011 | 1892 | 0.020 |
Why?
|
| Holistic Health | 1 | 2010 | 9 | 0.020 |
Why?
|
| Self Report | 1 | 2012 | 297 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 247 | 0.020 |
Why?
|
| Sepsis | 1 | 2013 | 322 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 520 | 0.020 |
Why?
|
| Chronic Pain | 1 | 2011 | 162 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 818 | 0.020 |
Why?
|
| Time Management | 1 | 2008 | 9 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 125 | 0.020 |
Why?
|
| Employee Incentive Plans | 1 | 2008 | 4 | 0.020 |
Why?
|
| Personnel Loyalty | 1 | 2008 | 4 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 452 | 0.020 |
Why?
|
| Professional Autonomy | 1 | 2008 | 41 | 0.020 |
Why?
|
| Staff Development | 1 | 2008 | 27 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1152 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2008 | 158 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 785 | 0.020 |
Why?
|
| Rats | 1 | 1993 | 4044 | 0.020 |
Why?
|
| Workload | 1 | 2008 | 129 | 0.020 |
Why?
|
| Retreatment | 1 | 2006 | 108 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 225 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2006 | 76 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 92 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2008 | 233 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3461 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 684 | 0.020 |
Why?
|
| Social Behavior | 1 | 2008 | 299 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1442 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 2577 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1665 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 75 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1720 | 0.010 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2004 | 7 | 0.010 |
Why?
|
| Guanylate Kinases | 1 | 2004 | 12 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 136 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2004 | 63 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 231 | 0.010 |
Why?
|
| Cytosol | 1 | 2004 | 193 | 0.010 |
Why?
|
| Astrocytes | 1 | 2004 | 141 | 0.010 |
Why?
|
| Dendrites | 1 | 2004 | 102 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 387 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 756 | 0.010 |
Why?
|
| Animals | 3 | 2011 | 27445 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1802 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2884 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1225 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 3229 | 0.010 |
Why?
|
| Gene Conversion | 1 | 1993 | 24 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1993 | 173 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 156 | 0.010 |
Why?
|
| Gene Library | 1 | 1993 | 133 | 0.010 |
Why?
|
| Codon | 1 | 1993 | 122 | 0.010 |
Why?
|
| DNA Primers | 1 | 1993 | 544 | 0.010 |
Why?
|
| Dogs | 1 | 1993 | 704 | 0.010 |
Why?
|
| Primates | 1 | 1993 | 155 | 0.010 |
Why?
|
| Swine | 1 | 1993 | 587 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 922 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 1089 | 0.010 |
Why?
|
| Skin | 1 | 1993 | 585 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 2331 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 3027 | 0.010 |
Why?
|
| DNA | 1 | 1993 | 1309 | 0.000 |
Why?
|